152 related articles for article (PubMed ID: 38165296)
1. Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.
Loomis SJ; Miller R; Castrillo-Viguera C; Umans K; Cheng W; O'Gorman J; Hughes R; Budd Haeberlein S; Whelan CD
Neurology; 2024 Feb; 102(3):e207919. PubMed ID: 38165296
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
[TBL] [Abstract][Full Text] [Related]
3. Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
Filippi M; Cecchetti G; Spinelli EG; Vezzulli P; Falini A; Agosta F
JAMA Neurol; 2022 Mar; 79(3):291-304. PubMed ID: 35099507
[TBL] [Abstract][Full Text] [Related]
4. Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab.
VandeVrede L; Gibbs DM; Koestler M; La Joie R; Ljubenkov PA; Provost K; Soleimani-Meigooni D; Strom A; Tsoy E; Rabinovici GD; Boxer AL
Alzheimers Dement (Amst); 2020; 12(1):e12101. PubMed ID: 33072846
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis.
Jeong SY; Suh CH; Shim WH; Lim JS; Lee JH; Kim SJ
Neurology; 2022 Nov; 99(19):e2092-e2101. PubMed ID: 36038268
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
[TBL] [Abstract][Full Text] [Related]
7. Aducanumab: Appropriate Use Recommendations Update.
Cummings J; Rabinovici GD; Atri A; Aisen P; Apostolova LG; Hendrix S; Sabbagh M; Selkoe D; Weiner M; Salloway S
J Prev Alzheimers Dis; 2022; 9(2):221-230. PubMed ID: 35542993
[TBL] [Abstract][Full Text] [Related]
8. Artificial Intelligence Assistive Software Tool for Automated Detection and Quantification of Amyloid-Related Imaging Abnormalities.
Sima DM; Phan TV; Van Eyndhoven S; Vercruyssen S; Magalhães R; Liseune A; Brys A; Frenyo P; Terzopoulos V; Maes C; Guo J; Hughes R; Gabr RE; Huijbers W; Saha-Chaudhuri P; Curiale GG; Becker A; Belachew S; Van Hecke W; Ribbens A; Smeets D
JAMA Netw Open; 2024 Feb; 7(2):e2355800. PubMed ID: 38345816
[TBL] [Abstract][Full Text] [Related]
9. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.
Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM
J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765
[TBL] [Abstract][Full Text] [Related]
10. APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials.
Evans CD; Sparks J; Andersen SW; Brooks DA; Hauck PM; Mintun MA; Sims JR
Alzheimers Dement; 2023 Dec; 19(12):5407-5417. PubMed ID: 37204338
[TBL] [Abstract][Full Text] [Related]
11. Dissecting the role of Amerindian genetic ancestry and the ApoE ε4 allele on Alzheimer disease in an admixed Peruvian population.
Marca-Ysabel MV; Rajabli F; Cornejo-Olivas M; Whitehead PG; Hofmann NK; Illanes Manrique MZ; Veliz Otani DM; Milla Neyra AK; Castro Suarez S; Meza Vega M; Adams LD; Mena PR; Rosario I; Cuccaro ML; Vance JM; Beecham GW; Custodio N; Montesinos R; Mazzetti Soler PE; Pericak-Vance MA
Neurobiol Aging; 2021 May; 101():298.e11-298.e15. PubMed ID: 33541779
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid.
Yaari R; Holdridge KC; Choi J; Donohue MC; Kantarci K; Jack CR; Zuk SM; Sims JR; Johnson KA; Aisen PS; Sperling RA
J Prev Alzheimers Dis; 2022; 9(4):617-624. PubMed ID: 36281665
[TBL] [Abstract][Full Text] [Related]
13. Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.
Mallinckrodt C; Tian Y; Aisen PS; Barkhof F; Cohen S; Dent G; Hansson O; Harrison K; Iwatsubo T; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; von Hehn C; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A; Chen T; Budd Haeberlein S
J Prev Alzheimers Dis; 2023; 10(2):171-177. PubMed ID: 36946443
[TBL] [Abstract][Full Text] [Related]
14. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
Liu E; Wang D; Sperling R; Salloway S; Fox NC; Blennow K; Scheltens P; Schmidt ME; Streffer J; Novak G; Einstein S; Booth K; Ketter N; Brashear HR;
Neurology; 2018 Mar; 90(10):e877-e886. PubMed ID: 29429971
[TBL] [Abstract][Full Text] [Related]
15. Dissociable influences of
Ge T; Sabuncu MR; Smoller JW; Sperling RA; Mormino EC;
Neurology; 2018 May; 90(18):e1605-e1612. PubMed ID: 29592889
[TBL] [Abstract][Full Text] [Related]
16. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
Saddiki H; Fayosse A; Cognat E; Sabia S; Engelborghs S; Wallon D; Alexopoulos P; Blennow K; Zetterberg H; Parnetti L; Zerr I; Hermann P; Gabelle A; Boada M; Orellana A; de Rojas I; Lilamand M; Bjerke M; Van Broeckhoven C; Farotti L; Salvadori N; Diehl-Schmid J; Grimmer T; Hourregue C; Dugravot A; Nicolas G; Laplanche JL; Lehmann S; Bouaziz-Amar E; ; Hugon J; Tzourio C; Singh-Manoux A; Paquet C; Dumurgier J
PLoS Med; 2020 Aug; 17(8):e1003289. PubMed ID: 32817639
[TBL] [Abstract][Full Text] [Related]
17. A Time-to-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease.
Muralidharan KK; Karumanchi S; Kowalski KG; Burkett P; Chapel S; Rajagovindan R; Nestorov I
J Clin Pharmacol; 2022 Aug; 62(8):1030-1046. PubMed ID: 35285968
[TBL] [Abstract][Full Text] [Related]
18. Lecanemab: Appropriate Use Recommendations.
Cummings J; Apostolova L; Rabinovici GD; Atri A; Aisen P; Greenberg S; Hendrix S; Selkoe D; Weiner M; Petersen RC; Salloway S
J Prev Alzheimers Dis; 2023; 10(3):362-377. PubMed ID: 37357276
[TBL] [Abstract][Full Text] [Related]
19. Association of Uncommon, Noncoding Variants in the APOE Region With Risk of Alzheimer Disease in Adults of European Ancestry.
Blue EE; Cheng A; Chen S; Yu CE;
JAMA Netw Open; 2020 Oct; 3(10):e2017666. PubMed ID: 33090224
[TBL] [Abstract][Full Text] [Related]
20. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.
Yuksel JM; Noviasky J; Britton S
Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846
[No Abstract] [Full Text] [Related]
[Next] [New Search]
